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Abstract
Prostate cancer development is uniquely dependent on the androgen receptor’s (AR’s)
transcriptional regulation in response to hormone binding. Current therapies directly target AR
acting as an antagonist at androgen binding sites. However, once androgen-dependence is lost,
meaning the patient has progressed into a late-stage hormone resistant phenotype, all current
treatments are essentially ineffective. Utilizing the yeast strain Saccharomyces cerevisiae we are
capable of creating a model system that allows for the exogenous expression of AR while still
retaining the chaperone components needed for this steroid receptor complex (Schena et
al.,1988). The 52kDa FK506 binding protein (FKBP52) has been shown to be an important
positive regulator of AR receptor function (Cheung-Flynn et al.,2005). Additional analysis has
also identified a synergistic interaction occurring between FKBP52 and the cadherin-associated
protein known as β-catenin (Storer., unpublished data).
Data gleaned from yeast-reporter assays determined that within S. cerevisiae this
synergism is essentially lost. Previous research shows that the Inhibitor of β-catenin and T-cell
factor (ICAT) protein is capable of modulating AR activity within mammalian cells (Zhou et al.,
2011). Introduction of this protein within yeast, interestingly, resulted in a significant increase of
AR activity while in the presence of only FKBP52. His tagged pull-down assays determined that
there is no direct protein-protein interaction between the two. Instead, it is likely that FKBP52
and ICAT are capable of modulating AR activity directly on the receptor surface or can induce a
positive conformational change. This information can help us understand the multi-protein
complex that regulates AR activity for novel CRPC therapeutic sites.
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Chapter 1: Introduction
Androgens are essential for the normal differentiation of male reproductive organs as
well as the development and progression of prostate cancer (PCa) (Jenster., 1999). A common
treatment for patients with advanced PCa involves androgen depletion which typically results in
apoptosis of primary tumor cells, demonstrating the disease’s dependence on AR activation
(Kyprianou and Issacs., 1988). However, despite the initial response to treatment, tumor
development is likely to reoccur as castration-resistant prostate cancer (CRPC). During this
disease developmental phase current clinical therapeutic options are unsuccessful.
1.1 Steroid Hormone Receptors
1.1.1 Receptor Assembly
Steroid hormone receptors (SHRs) are transcription factors that are responsible for the
expression of hormone dependent genes. There are five main receptors in the SHR family, those
being the androgen (AR), glucocorticoid (GR), progesterone (PR), mineralocorticoid (MR), and
estrogen (ER) receptors (Pratt and Toft.,1997). Proper folding and activation of each SHR is
dependent upon the dynamic assembly of the chaperone and cochaperone machinery (Edwards.,
2000).
This assembly begins with the free cytosolic receptor binding to the cochaperone Heat
shock protein 40 (Hsp40) and chaperone Hsp70 (refer to figure 1.1) (Young et al., 2004). Hsp70
is responsible for the fate of the receptor, either allowing it to continue to the intermediate
complex or sending it for proteasomal degradation. If the receptor is damaged or missfolded, the
proteins Bcl-2 associated athanogene (BAG) and carboxy terminus of Hsc70 interacting protein
(CHIP) bind to Hsp70 and degrade the SHR via the ubiquitin-proteasome pathway (Connell et
al., 2001). However, if there are no significant issues with the early complex it is then capable of
proceeding to its next stage of maturation. This next phase allows for the Hsp 70-interacting
protein (HIP) to displace Hsp40 and stabilize Hsp70, increasing its affinity for substrates
(Whitesell and Lindquist., 2005). Following this, Hsp-organizing protein (HOP) in association
1

with Hsp90 is bound to the complex and results in the subsequent release of HIP, HOP and
Hsp70. The Hsp90 cochaperone p23 then stabilizes the Hsp90 conformation and proteins known
as immunophilins are recruited. These immunophilins are characterized by their Hsp-90 binding
tetratricopeptide repeat (TPR) domain, examples of which include Cyclophilin (CyP40), Protein
Phosphatase 5 (PP5) and the immunophilins our lab primarily study FKBP51 or 52 kDa. The
final mature complex allows for high affinity hormone binding. In the presence of hormone the
mature receptor dissociates from heat shock proteins, forms a homodimer, undergoes
phosphorylation, and subsequently translocates into the nucleus (Galigniana et al., 2001;
Claessens et al., 2008). Here, it binds to hormone response elements (HRE) and can begin
initiating gene transcription.
1.1.2 Androgen Receptor Structure and Function
It is also important to take into account the structure of AR as this will provide us with
information regarding its regulation and various protein interactions. There are four principal
domains that make up the receptor; the N-terminal domain, the ligand binding domain (located at
the C-terminus), the DNA binding domain, and the hinge region (figure 2) (Tsai et al., 1994;
White et al., 1998).
The N-terminal domain (NTD) contains activation function 1, one of the two activation
function (AF-1 or AF-2) sites found in AR. The activation domain’s posses the ability to activate
transcription, although the mechanisms by which it is capable of doing so is still not fully
understood (Jenster et al., 1995). The AF-1 region is the least conserved site amongst all SHR’s,
sharing only 15% homology (Lavery and McEwan., 2005). Coactivators are recruited to this
region in a ligand-independent manner. In addition, there are a varying number of polyglutamine
repeats within the (NTD) ranging from 8 to 31, the average being 20 (Quigley et al., 1995;
Heemers and Tindall., 2007). Lengthening these repeats can give rise to mild androgen
2

Figure 1.1: Steroid Hormone Receptor Maturation

Cytosolic SHR (R) initially binds to Hsp40 and Hsp70 forming an early complex. Upon binding
Hsp70 the receptor is either targeted for proteosomal degradation or can continue towards an
intermediate complex. HIP and Hop are recruited allowing for Hsp90 binding. At the last stage
of the pathway the cochaperone p23 and an immunophilin (I) are recruited creating the final
mature high affinity hormone binding complex. The receptor is then capable of translocating into
the nucleus to begin gene transcription. Figure created by Marc B. Cox, Ph.D.
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insensitivity, while shortening them has been shown to increase AR transcriptional activity. The
N-terminal domain also contains a FxxLF and WxxLF motif that is responsible for its interaction
with the C-terminal domain stabilizing AR/ligand interactions (He et al., 2002). This N and C
terminal interaction was determined to be preferable over co-activator recruitment and is distinct
for AR, which could possibly act as a novel drug regulatory site.
AF-2 is found within the ligand binding domain (LBD) and, opposite from AF-1, is highly
conserved and its coactivator binding is ligand-dependent. The crystal structure of AR’s ligand
binding domain shows it contains 11 α-helices (labeled 1-12 in consistence with other SHR’s,
however no second helix exists) and two short β-turns (Matias et al., 2000). The ligand binding
pocket, also known as Binding Factor 1 (BF-1), consists of helices 3, 5, 10, and 11. Upon
hormone binding there is a conformational change and helix 12 repositions itself acting as a “lid”
stabilizing the binding pocket/ligand interaction. This shift also allows for the activation of the
hydrophobic AF-2 site. Co-activators containing an LxxLL motif within their nuclear receptorinteracting domain (NID) are recruited for binding to this surface (Heery et al., 1997). The
FxxLF and WxxLF motifs in the NTD can compete with co-activators for binding at the AF-2
site, which as previously stated is a preferable interaction (He et al., 2002). Removal of the
ligand binding domain gives rise to a constitutively active AR. Also located next to the AF-2
coactivator binding site within the LBD, is the newly characterized Binding Factor 3 (BF3)
surface (Estébanez-Perpiñá et al., 2007; Buzón et al., 2011). This surface is similarly
hydrophobic in nature. Screening of compounds that targeted this area resulted in a down
regulation of AR mediated transcription and prevented certain co-activators from binding. Based
on this information our lab previously developed the compound MJC13 which, through in-silico
docking simulations, is predicted to bind to AR’s BF3 surface (De Leon et al., 2011).

4

FXXLF

WXXLF

Figure 1.2: Schematic of Human AR

Representation of AR domains and the exons that encode for them. AR is composed of an Nterminal domain, which has the AF1 site and FxxLF/WxxLF motifs, and a Ligand binding
domain, containing the AF2 site and BF3 surface. There also is a short hinge region and a highly
conserved DNA binding domain. (Cox et al., 2005)
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AR’s DNA binding domain (DBD) is well conserved amongst SHR’s demonstrating their
common need to bind DNA, however their sequential differences highlight their selectiveness of
particular genes. The mature AR homodimer binds to the androgen response element site
through the first of its two zinc fingers while the second is involved in AR dimerization
(Heemers and Tindall., 2007). There also is a nuclear localization signal (NLS) that spans the
DBD and hinge region (Jenster et al., 1993; Zhou et al., 1994).

1.2 FKBP52
1.2.1 FKBP51 and FKBP52
The Immunophilin known as the 52 kDa FK506 binding protein (FKBP52) has been
found to be a positive regulator of AR (Cheung-Flynn et al., 2005), PR (Tranguch et al., 2005),
and GR (Riggs et al., 2003) in both cellular and whole animal models. FKBP52 belongs to the
FKBP family of co-chaperones through its interaction with the immunosuppressive drug FK506
(also known as Tacrolimus). The immunosuppressive effects caused by FK506 only occur
through its interaction with FKBP12’s peptidyl-prolyl cis-trans isomerase (PPIase) pocket,
creating a high affinity calcineurin interaction surface. The clinical success of Tacrolimus
demonstrates that the hydrophobic PPIase pocket within the FKBP family is a druggable
interaction surface having insignificant off-target effects.
FKBP51 is another member of the FKBP family that shares a significant amount of
similarity to FKBP52. They both modulate SHR activity through the binding of Hsp90 as well as
share a similar conformation. In fact, there is 70% homology in amino acid sequence conserved
between the two (Figure 1.3). Both contain three functional domains and a short linker region.
These include the FKBP12-like domain 1 and 2 (FK1 and FK2) as well as a Tetratricopeptide
repeat (TPR) domain. The FK1 domain of both FKBP51 and FKBP52 has functional PPIase
6

activity while the FK2 domain in both immunophilins lack this. The TPR domain remains highly
conserved and allows for interaction with Hsp90 by way of the C-terminal EEVD motif. The FK
linker (also known as the FK loop) connects the FK1 and FK2 domains and is also capable of
regulation. This region contains the 143-TEEED sequence within FKBP52 and a 143-FED
sequence in FKBP51. The 143-TEEED sequence is phosphorylated by casein kinase 2 resulting
in the reorientation and subsequent loss of function of the FK1 domain. Alternatively, the 143FED sequence in FKBP51 lacks the Threonine phosphorylation site demonstrating a possible
functional difference between the two proteins. The FKBP52 mutant, T143E, resulted in an
abrogation of FKBP52’s functional effects on the androgen receptor demonstrating that the FKloop is another potential therapeutic site. The N-terminal FK1 domain in FKBP52 was
discovered to be essential for AR regulation; however, the PPIase enzymatic activity was not
responsible for the resulting potentiation. Instead, domain mapping studies have reported that the
proline-rich loop that overhangs the PPIase catalytic pocket is critical for receptor regulation and
may be a potential interaction surface (Riggs et al., 2007). FKBP51 is not capable of potentiating
AR activity, and instead acts as a negative regulator on the receptor. However, random
mutagenesis determined that the mutations A116V and L119P converted FKBP51 to a fully
functional FKBP52-like state, capable of AR potentiation. Again, highlighting the importance of
the FK1 proline-rich loop.
SHR’s are found to reside within the nucleus and cytoplasm in the absence of ligand with
their main method of transport believed to be simple diffusion. Recently, it was discovered that
FKBP52 was co-immunoprecipitated in complex with Hsp90 and the dynein/dynactin complex,
suggesting the use of retrograde transport. FKBP52’s PPIase domain binds the dynein/dynactin
motor complex independently of its PPIase activity. Instead the FK1 domain acts as a protein-
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protein interaction domain. Treatment with geldanamycin (a Hsp90 inhibitor) increased the
transport time of the steroid hormone receptors, MR and GR, from the cytoplasm into the
nucleus by roughly 11-fold.
Murine studies have also demonstrated that FKBP52 plays a significant role in male
sexual development and reproduction. Fkbp52 knock-out (52KO) mice were developed by
removing exons that coded for the 52 protein. The resulting male mice displayed a phenotype
similar to that of an androgen insensitivity syndrome (Cheung-Flynn et al., 2005; Yong et al.,
2007). Morphological traits of 52KO mice included ambiguous external genitalia, dysgenic
seminal vesicles, and a retention of nipples into adulthood. Female mice also showed a loss of
fertility and development of endometriosis, while displaying no phenotypic differences (Hirota et
al., 2008; Tranguch et al., 2005). Loss of FKBP51 expression within mice did not result in any
morphological differences, however the loss of FKBP51 and FKBP52 proved to be
embryonically lethal. This suggests some possible redundancy in the roles of FKBP51/52.
Regulation of AR activity requires the binding of FKBP52 to Hsp90 however, it is still
unknown if FKBP52 is capable of directly interacting with the receptor. The use of chimeric
receptor proteins has established that the FK1 site, specifically the proline-rich loop, of FKBP52
is a likely regulator at the receptor’s LBD (Riggs., et al. 2003). Yeast studies also demonstrated
that mutations on the AR BF3 surface increased its dependency of FKBP52. A compound library
yeast screen determined that the small molecule inhibitor, MJC13, was capable of inhibiting AR
function by preventing the hormone-induced release of the Hsp90-AR complex (De Leon et al.,
2011). Available evidence suggests that the compound MJC13 binds to the BF3 surface of AR at
the possible FKBP52 interaction site.

8

Figure 1.3: Structure of FKBP51 and FKBP52

FKBP51 and FKBP52 are composed of four domains. The FK1 domain, which confers PPIase
activity and contains the Proline rich loop. The FK linker which connects the FK1 domain to
FK2 and regulates FKBP52 functionality though phosphorylation from casein kinase 2 (CK2).
FK2, which is structurally similar to FK1 however, it lacks PPIase activity. Lastly, the TPR
region is responsible for binding to the EEVD motif of Hsp90 though its tetratricopeptide repeats
(TPR) (Harris et al., 2014).

9

1.3 Beta-Catenin’s Synergistic Effect
β-Catenin is a multifunctional protein that is involved in several signaling pathways and
has implications in cell-cell adhesions (McCrea and Gumbiner., 1991; Pandur et al., 2002). In the
latter role, β-Catenin is key in the linking of cadherin’s cytoplasmic tail to α-catenin and the actin
cytoskeleton. It is also capable of acting as a transcription factor within the canonical Wnt
signaling pathway through its interaction with the LEF1/TCF (lymphoid enhancer factor/T Cell
factor) family of proteins. More importantly, β-Catenin has recently been established as a well
known regulator of AR mediated transcription (Yang et al., 2002).
It has a relative size of 92kDa and is composed of 12 armadillo repeats, a 140 amino acid
N-terminus regulatory site, and a roughly 100 amino acid C-terminus trans-activation domain
(McCrea et al., 1991). One armadillo repeat is composed of 42 amino acids arranged in three αhelices, designated H1, H2, and H3 (except for repeat 7 which lacks H1). The H3 helices allow
for the formation of a positively charged groove extending from repeat 1 to 10 and a
hydrophobic surface at repeats 11 and 12. Structural analysis has determined that the β-Catenin
ligands human Tcf-4, E-cadherin, and APC all interact through similar mechanisms at the
positive groove region between repeats 5 and 10 at two lysine residues called charge buttons
(Huber et al., 1997).
Immunoprecipitation assays have demonstrated that AR complexes with β-Catenin in
LNCaP cell lines, and even more so in the presence of hormone. Yet, there is no crystal structure
demonstrating β-Catenin’s direct interaction with AR or FKBP52. However, its interaction with
the liver receptor homolog-1 (LRH-1), a member of the nuclear receptor subfamily, ligand
binding domain was solved and superposed over analogous sites in AR (Figure 1.4) (Fletterick.,
2009). This demonstrated that the armadillo repeats 3-7 of β-Catenin bound to a region similar to
10

Figure 1.4: Model of β-Catenin Interaction With AR

Predicted model of AR interaction with β-Catenin shows binding site overlaps with the predicted
FKBP52 regulatory site (BF3 surface). This interaction occurs through the Flufeamic acid
(purple), β-Catenin (green), LBD (teal) (Fletterick., 2009)
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the AF-2 and BF3 surface of AR. Following small molecule binding at the AR BF3 surface the
AF-2 site endures a conformational change, possibly allowing for the formation of a β-Catenin
interaction surface. This suggests that since the BF3 surface is the hypothesized FKBP52
interaction site, there may be a cooperative multi-protein complex directly regulating the
androgen receptor.
Previous research within our lab investigated the effect of β-Catenin and FKBP52
overexpression on AR transcriptional activity within a fkbp52 knock-out mouse embryonic
fibroblast cell line (52KO MEF) (Storer., unpublished data). This determined there to be a
synergistic up regulation of said activity. The data revealed that FKBP52 and β-Catenin worked
in concert with one another, losing this synergism if the other protein was not expressed (figure
1.5). Preliminary research on β-Catenin had indicated it acting alone on its synergism of AR
however, these studies did not utilize cell lines that lacked FKBP52.
Cellular β-Catenin levels have been found to be increased in not only prostate cancer, but
also in a variety of human cancers, such as hepatocellular carcinoma (Miyoshi et al., 1998),
medulloblastoma (Zurawel et al., 1998), endometrial cancer (Fukuchi et al., 1998), and ovarian
cancer (Palacios et al., 1998). Therapeutically targeting this protein is an unlikely clinical
treatment due to its involvement in cell-cell adhesions. Instead, it is of particular interest to study
its interactions with the Androgen receptor and FKBP52 for potential target sites in prostate
cancer.

12

Figure 1.5: β-Catenin Overexpression Results in a Synergistic Effect Within 52KO MEFs.

β-catenin acts in synergy with FKBP52 in order to promote AR signaling within 52KO MEFs.
The β-cat S33A mutant is resistant to GSK3β phosphorylation and subsequent degradation.
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1.4 Prostate Cancer Development
1.4.1 Facts and Statistics
While cancer has no definitive origin, the fundamental abnormality that results in disease
development is the continual unregulated growth of cancerous cells. Causes of cancer can
include genetic irregularities, environmental exposure, infection with a pathogen, or lifestyle
factors. Within the United States alone, there was an estimated 14 million citizens that reported a
history of cancer (American Cancer Society., 2014). In addition, approximately 600,000
American’s are expected to die as a result of cancer, making it the second most common cause of
death in the U.S., behind heart disease.
Prostate cancer is the second most frequently diagnosed cancer in men, as well as the
second leading cause of cancer death. There was an estimated 233,000 new cases in the U.S.
during 2014 with a higher incidence rate was seen in African Americans males than in nonHispanic whites. In addition, the National Cancer Institute asserts that PCa is more common in
older men with a family history of the disease. It is most frequently diagnosed in males aged 6574, which roughly accounts for 36.8% of all new PCa cases (American Cancer Society., 2014).

1.4.2 Clinical Diagnosis
Prostate cancer symptoms are generally mild and include frequent or difficult urination,
erectile dysfunction, and/or blood in the urine or semen. Symptoms are similar to that of the
enlargement of the urethral prostate tissue, known as benign prostatic hyperplasia (BPH).
However, outcomes of both diseases are vastly different as BPH is non-cancerous, ordinarily
treatable and can result in urinary tract and kidney problems. Prostatic intraepithelial neoplasia
(PIN) and proliferative inflammatory atrophy (PIA) are two other conditions that display
abnormal prostate gland cells within a biopsy (American Cancer Society., 2014). Research
14

suggests these may be a pre-cancerous state of the prostate. However, no definitive data has
stated a direct correlation between these conditions and PCa development.
Diagnosis of prostate cancer occurs through the use of a prostate specific antigen (PSA)
blood test. This involves the use of a blood sample to determine PSA levels within the
individual. An increase of PSA levels is correlated with an increase in risk of tumor
development, with majority of healthy men having PSA levels under 4 ng/mL of blood. Patients
with PSA levels greater than 10 ng/mL typically have a 50% chance of having prostate cancer.
The most widely used staging system for prostate cancer is the American Joint
Committee on Cancer (AJCC) TNM System. This looks at the extent of the primary tumor (T),
whether it has spread to the lymph nodes (N), the absence or presence of distant metastasis (M),
the PSA level at the time of diagnosis, as well as the Gleason score, which determines the extent
to which the prostate tissue has altered to a cancerous state. Following the assembly of data the
overall stage of the individuals PCa is scored in Roman numerals ranging from I to IV, with I
being the least advanced and IV being the most. This helps in determining the patient’s prognosis
and expected survival.
Late-stage castrate resistant prostate cancer is developed when the tumor is no longer
responsive to low-dose treatment of testosterone within the body. Currently, CRPC is an
incurable disease and has a relatively low survival rate.

1.4.3 Genomic Aberrations
Inherited changes in DNA account for roughly 5 to 10% of total prostate cancer cases in
the U.S. (American Cancer Society., 2014). Out of these changes, several of the cell’s tumor
suppressor genes have been found to be mutated. These include BRCA1 and BRCA2, which are
responsible for repairing double-stranded DNA breaks. Carriers of BRCA1/2 mutations had a
15

relative risk of prostate cancer development of 4.65 by age 70 as well as an increased risk for
other cancers such as pancreatic cancer, leukemia and lymphoma, as well as ovarian and breast
cancer in women (Levy-Lahad and Friedman., 2007; Friedenson., 2007). However, only 1-2% of
prostate cancers are believed to be caused by BRCA1 or BRCA2 mutations (Levy-Lahad and
Friedman., 2007).
The ubiquitin ligase speckle-type POZ protein (SPOP) is mutated in 6-15% of prostate
cancer cases. A few pro-oncogenic proteins targeted by SPOP include DEK (Theurillat et al.,
2014), the P160 steroid receptor co-activators (SRCs) NCOA1, 2 and 3 (Gregory et al., 2001;
Genge et al., 2013) as well as the androgen receptor itself ( An et al., 2014). SPOP mutations
prevent P160 SRC family proteins from being targeted for degradation and instead results in
their accumulation. Overexpression of these proteins is linked to prostate cancer cell survival and
can increase AR transactivation. The transcription factor GATA2 enhances the recruitment of
NCOAs to the AR complex and is also found to co-localize with the forkhead protein (FOXA1)
(He et al., 2014). FOXA1 was also determined to be genetically mutated in a small subset of
prostate cancers as well as amplified or even deleted (Taylor et al, 2010; Grasso et al, 2012).
In addition, RNASEL which encodes for ribonuclease L (RNASEL), is a member of the
interferon-mediated immune response and is found to mutated in a small percentage of CRPC
cases (Liang., 2006). Infectious agents can result in intraprostatic inflammation leading to the
damage of local tissue, which may in turn drive cancer progression. RNASEL is responsible for
cleavage of viral RNA as well as induction of apoptosis. Advanced stages of disease were
associated with the missense mutations R462Q and D541E within RNASEL.
AR mutations are also detectable in some CRPC patients with majority of these being in
the LBD or co-factor binding regions (Gottlieb et al, 2012; Grasso et al, 2012). These mutations
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have the capability of activating AR through other steroid metabolites. For example, the
mutation L702H is able to repurpose glucocorticoids as AR ligands. Androgen receptor variants
have also been found to be able to convert AR antagonists into AR agonists.
Following severe ligand depletion, a common issue CRPC patients face is the increase of
AR gene transcription due to the cells innate feedback response (Wolf et al, 1993; Cai et al,
2011; Knuuttila et al, 2014; Wyatt et al, 2014). This overexpression of AR is driven by
rearrangement of the X chromosome and leads to a hypersensitivity of castration levels of DHT.
Increase of AR transcription pressure can also lead to hormone independent splice variants.
These AR splice variants (AR-Vs) lack the LBD leaving them constitutively active. Those
positive for the AR-V7 truncations are associated with primary resistance to the drugs
abiraterone and enzalutamide (Dehm et al., 2011).

1.5 Current Treatment Options
1.5.1 Surgery and Radiation Therapy
The initial treatment response for low-grade prostate cancer involves either the use of
radiation therapy or surgery. It is performed at an early disease development phase, typically
stage I, which identifies the cancer as being localized to the prostate gland. Both surgery and
radiation have a similar success rate and are routinely used in conjunction with one another to
strengthen the possibility of total cancer eradication . (American Cancer Society., 2014).
Two types of radiation treatments are currently available to treat prostate cancer, these
being external beam radiation therapy (EBRT) and brachytherapy. EBRT involves the use of a
machine that focuses radiation beams on the prostate gland and is performed outside of the body.
Brachytherapy (also known as seed implantation radiation therapy) utilizes small radioactively
labeled pellets that are placed directly into the prostate. These “seed” sized pellets are inserted
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through the use of a needle and either give off low doses of radiation for several weeks, or
release high doses in a very short time period (typically two days). Both external and internal
radiation run the risk of causing bowel and urinary problems, however, serious long-term issues
occur in less than 5% of patients.
Surgery is a common treatment option and the predominant operation performed is
known as a radical prostatectomy. This involves the removal of the entire prostate gland, as well
as the surrounding tissue, seminal vesicles, and if necessary, nearby lymph nodes. Several
surgical approaches are available, examples of which include a radical retropubic and radical
perineal prostatectomy. Both of which involve invasive surgical incisions and are used less often
than the third surgical approach, known as laparoscopic radical prostatectomy (LRP). LRP
instead uses small incisions in which surgical instruments are inserted into and are controlled
either manually or robotically by the surgeon. Side effects are similar to those of radiation
therapy, and also include an increased risk of the loss of fertility, lymphedema, and inguinal
hernia development.

1.5.2 Androgen Deprivation Therapies
If the disease develops into a late-stage metastatic form, surgery and radiation are no
longer considered viable treatment options. Instead, therapy then focuses on targeting the ligands
responsible for androgen receptor activity or a direct target of the receptor itself. Research has
demonstrated that majority of all prostate cancers exhibit a response to the depletion of
circulating androgens within the body. Because of this, androgen deprivation therapy (ADT) has
been a staple in late stage prostate cancer treatment for nearly three-quarters of a century
(Huggins et al., 1941).
The production of DHT can be halted through a variety of different means. Obstruction
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of Testosterone synthesis can be achieved through the blockage of members of the cytochrome
P450 (CYP) family of enzymes. These enzymes are responsible for the catalytic conversion of
cholesterol into testosterone (Figure 1.6). The drug known as abiraterone acetate targets the CYP
family enzyme CYP17A1, and has demonstrated significant improvement in median overall
survival during phase III clinical trials (Fizazi et al., 2012; Ryan et al., 2013). Due to the relative
success of abiraterone other CYP17A1 inhibitors, examples of which include Orteronel, VT-464,
and Galeterone, were developed and are currently in phase I and II clinical trials. In addition,
other members of the steroid hormone pathway have the potential of being therapeutically
targeted. Dutasteride (brand name Avodart) inhibits the type 1 and type 2 5-alpha-reductase
catalysis of testosterone to DHT (Steers et al., 2001). Following initial ADT the minor
testosterone synthesis pathway that utilizes circulating DHEA-S derived from the adrenal glands
remains capable of androgen synthesis through the aldo-keto reductase family 1, member C3
(AKR1C3) (Lin et al., 1997). The oral AKR1C3 inhibitor ASP9521 was terminated during phase
I/II clinical trials due to ineffectiveness however, it is likely required to be used in combinational
therapies to block one of the multiple pathways involved in DHT synthesis.
DHT synthesis can also be blocked through the use of luteinizing hormone releasing
hormone (LHRH) agonists and antagonists, which interfere with the hypothalamic-pituitarytestis axis. The agonistic drug leuprolide works by stimulating a sizable release of lutenizing
hormone (LH) from the pituitary gland. This increases testosterone production in the testis and
adrenal glands. Through negative feedback inhibition the production of LH is dramatically
reduced, subsequently down regulating testosterone production. Unfortunately, LHRH agonists
result in an initial surge of testosterone synthesis lasting several weeks. This could result in
spinal cord compression, increased pain at metastatic sites, as well as possible
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Figure 1.6: Alternative DHT Production Pathways

Testosterone synthesis relies on the P450 (CYP) family of enzymes. CYP proteins are targeted
by the drug Abiraterone.acetate. Various other testosterone producing pathways, and the
respective inhibitory drugs, are depicted above. (Cai and Balk.,2011)
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sudden death (Brawer., 2004) Conversely, the LHRH antagonist known as degarelix obstructs
LHRH-receptor binding within the pituitary gland preventing the release of LH. Treatment with
LHRH antagonists does not surge testosterone levels as with agonists but alternatively, results in
a rapid suppression of testosterone levels. The LHRH antagonist does not come without its share
of side-effects as it is capable of inducing possible life-threatening histamine-mediated allergic
reactions.
Directly targeting the androgen receptor is another therapeutic option in treating late-stage
CRPC, and is typically utilized following the failure of a LHRH analogue and/or orchiectomy.
These non-steroidal anti-androgens work by competing with hormone for AR binding at its LBD.
This prevents the receptor from becoming activated and in turn prevents AR mediated
transcription. Examples of AR antagonist include Bicalutamide, Flutamide, and Enzalutamide.
Bicalutamide is the more widely used anti-androgen as it has less hepatotoxicity as well as a
longer half life allowing for low-dose administration. AR-V expression has been detected in
CRPC patients that have garnered a resistance to abiraterone and enzalutamide (Antonarakis et
al, 2014). These truncations can be left unaffected by conventional AR therapeutics thus,
highlighting the necessity of new target sites..

1.5.3 Alternative Treatment Options
Following resistance to hormone therapy, the next treatment option typically involves the
use of the chemotherapeutic agent, docetaxel (Taxotere). This acts as an antimicrotubule agent
preventing its dissasembly, consequently resulting in the inhibition of mitotic cell division.
Another possible treatment option is the use of the cancer vaccine known as sipuleucel-T
(Provenge). Treatment involves the removal of dendritic cells from the patient. These are
subsequently incubated with the prostatic acid phosphatase (PAP) antigen, as well as the
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granulocyte-macrophage colony stimulating factor (GM-CSF), which promotes dendritic cell
activation. The activated antigen presenting cell’s are then re-infused into the patient and elicit
an immune response against cancer cells expressing the PAP antigen.
Following the invasive procedure of surgical castration, the body undergoes a
stress response that can induce heat-shock protein activity, preventing AR degradation. An
example of which includes overexpression of Hsp27. Phosphorylation activates this chaperone
which in turn enhances AR stability as well as promotes its nuclear transport and transcriptional
activity. Prevention of S78 and S82 residues from being phosphorylated or directly targeting
Hsp27 through the use of the drug OGX-427 promotes AR association with the E3 ubiquitin
ligase MDM2 stimulating AR proteosomal degradation (Zoubeidi et al., 2007). OGX-427 is
currently under phase II trials and has demonstrated, when in conjunction with prednisone
treatment, there was a greater decline in PSA levels in addition to a higher percentage of
progression free patients in comparison of treatment with prednisone alone. Targeting the Hsp90
is of clinical importance also as a majority of cancers accrue a high volume of missfolded
proteins due to rapid expression. Hsp90 helps the progression of prostate cancer into a castrateresistant state by refolding and promoting protein functionality. The small molecule inhibitor
known as ganetespib (STA-9090) targets the N-terminal ATP pocket within Hsp90 (Heath et al.,
2013). Despite promising preclinical studies, ganetespib did not demonstrate any advantage
during phase II clinical trials in CRPC patients (Heath el at., 2013). It is highly likely that
targeting only one chaperone is ineffective in the treatment of CRPC, instead a multi protein
attack is needed to overwhelm the cellular system and to prevent the development of drug
resistance.
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Chapter 2: Materials And Methods
2.1 Plasmid Development
For the reporter assays examining FKBP52 and β-Catenin synergy DNA cloning of
respective cDNA into a yeast expression vector was necessary. FKBP52 was previously made by
D. Riggs and is under a GPD promoter within a p424 plasmid. This vector is a 2u replicon and
contains a Tryptophan screening marker, allowing for growth within SC-W yeast dropout media,
as well as ampicillin resistance, for growth within Escherichia coli. The β-Catenin vector was
made using the β-Catenin cDNA sequence derived from the pSPORT6 vector purchased through
Open Biosystems. This was then inserted into the multiple cloning site of p413GPD at the
BamHI and ClaI sites. The p413GPD vector is a CEN6/ARSH4 replicon and contains a Histidine
3

marker

and

Ampicillin

resistance.

CGGATCCATGGCTACTCAAGCTGATTTGATGG-3’)

Primers

hBeta_CateninF

(5’-

and hBeta_CateninClaI.Rv (5’-

ATATCGATTTACAGGTCAGTATCAAA-3’) were used at 60 °C for the polymerase chain
reaction. The insert and vector were then digested with the BamHI and ClaI restriction enzymes
for 2 hours at 37°C. This was then ligated using (New England Biolab) T4 DNA Ligase at room
temperature overnight. The ligation product was transformed into DH5α competent cells and
resulting colonies were screened through restriction digest, then confirmed by sequencing. Due
to the number of plasmids being transformed into S. cerevisiae the cDNA encoding for ICAT
was inserted into a pBEVY-A vector. This vector contains bi-directional GPD and ADH
promotors allowing for the concurrent expression of two separate genes. ICAT was amplified
from the pBS-CMV-FLAG-ICAT plasmid (provided by Dr. Zijie Sun’s laboratory) using the
primers ICAT_BamHI.Forward (5’-TATAGGATCCATGAACCGCGAGGGAGCTCCCGG-3’)
and ICAT_SalI.Reverse (5’-TATAGTCGACCTACTGCCTCCGGTCTTCCGTCTCCGA-3’).
23

The pBEVY-A vector and ICAT insert region were then digested using the appropriate enzymes,
ligated, and transformed in a similar manner as the p413GPD_ β-Catenin plasmid.

2.2 Yeast Reporter Assay
β-Catenin and FKBP52 were individually as well as jointly expressed in a yeast-based ARmediated β-galactosidase reporter system. The yeast utilized was based on a W303a genetic
background (MATa leu2-112 ura3-1 trp1-1 his3-11,15 ade2-1 can1-100 GAL SUC2) containing
a URA3-marked β-galactosidase reporter plasmid and a LEU2-marked Androgen receptor
plasmid. FKBP52 (TRP3- marked) and β-catenin (HIS3-marked) or their respective vectors were
then transformed and grown on SC-LUHW plates for 3 days at 30°C. Three yeast isolates from
each plate were chosen for each triplicate and grown in 5ml of SC-LUHW shaking overnight. An
initial curve was created to determine the optimal concentration of DHT for the reporter assay.
This demonstrated that the EC50 of the curve, around 10-30nM, should be utilized. Yeast were
then grown overnight in 5ml of the appropriate media and subsequently diluted to an OD600 of
0.08. This dilution ensures equal logarithmic growth and was monitored fifteen minutes later
using spectrophotometry. Following this, the appropriate concentration of dihydrotestosterone
(DHT) or 100% ethanol was added to the diluted samples and allowed to shake at 30°C for two
hours. In order to measure the resulting β-galactosidase expression, 100ul of the culture grown
for two hours and 100ul of Gal-Screen TM substrate (Applied Biosystems) were combined in a
96-well plate and incubated at room temperature for another two hours. After this incubation the
plate was read in a luminometer (BioTek). Relative light units (RLU) were measured against the
resulting OD600 of each culture and the normalized data was plotted in GraphPad Software. 2.2

24

Figure 2.1: Steroid Hormone Yeast Assay

β-catenin and FKBP52 are individually as well as jointly expressed in a yeast-based ARmediated β-galactosidase reporter system. The activated AR then binds to the hormone response
element and results in transcription of the β-galactosidase reporter. The resulting β-gal
expression levels allow us to take a direct quantitative measurement of AR activity through the
use of a luminometer. Figure created by Marc B. Cox, Ph.D.
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2.3 Western Blot of Yeast Lysates
To ensure that the changes we are seeing with reporter expression is not due to variations
in protein expression, yeast lysates were prepared from the previous assay. Protein
concentrations were determined through the use of a bradford assay and a total of 35 ug was
loaded into each well. The proteins were then separated through electrophoresis and
subsequently transferred onto an Immobilon membrane (Millipore, Bedford, ME). The primary
antibodies used were β-Catenin (Santa Cruz, Santa Cruz, CA), anti-FKBP52 Hi52D (AbCam,
Cambridge, MA), anti-AR (Santa Cruz, Santa Cruz, CA) and anti-L3.

2.4 In Vitro Pull-Down of 6xHis-Tagged FKBP52
500ng of 6xHis tagged FKBP52 and 500ng of Myc-FLAG tagged ICAT (purchased
through Origene) recombinant proteins were utilized for an in-vitro pulldown to determine if
they are capable of direct binding. 300ul of Qiagen Ni-NTA agarose beads were spun down at
800g’s for 30 seconds. These were then washed three times with 1mL of cold buffer solution
(1% Tween 20, 5mM Imidazole, 1x PBS). The beads were resuspended in 1mL of buffer and
100ul was aliquoted into each prelabelled microcentrifuge tube. 500ng of the required protein
was then added into correct tumes. In addition, 50mM of MgCl2 was added and the total volume
was brought up to 500ul using cold Buffer. This was then incubated for 1 hour rotating in the
4°C walk in fridge. Following incubation the beads were subsequently spun down and washed in
1ml of buffer. This wash was repeated four more times then the beads were resuspended in 25ul
of 4x SDS-PAGE Gel loading buffer + 10% β-mercaptoethanol. Tubes were then incubated at
90°C for 5 minutes and then the sample was loaded onto a GenScript ExpressPlus™PAGE Gel
(4-20%). Following electrophoresis the proteins were transfered onto a Immobilon membrane
(Millipore, Bedford, ME). Primary antibodies anti-ICAT (FL-81)(Santa Cruz, Santa Cruz, CA),
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and anti-FKBP52 Hi52D (AbCam, Cambridge, MA) were used.
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Chapter 3: Results And Discussion
3.1 FKBP52 and Beta-Catenin’s Effect on AR Synergy Within a Yeast Model System
Based on previous data it can be inferred that FKBP52 works in cooperation with βCatenin to promote AR activity, even in yeast (Storer., Unpublished data). However, the results
gleaned from this study not only indicate that FKBP52 and β-Catenin are unable to have a
synergistic reaction when co-expressed, but also that the expression of β-Catenin inhibits
FKBP52 potentiation on the androgen receptor. β-Catenin expressed alone shows a slight
increase in AR activity however, when expressed in conjunction with FKBP52 the total reporter
expression appears to have become an average of the two.
Protein Expression levels within the western blot indicate that β-Catenin and AR are
stabilized when co-expressed. This could possibly be due to them forming a complex preventing
their degradation or dissociation of AR co-factors.

3.1.1 Identification of Other Factors Necessary for Beta-Catenin Induced Synergism
The previous yeast reporter assay demonstrated that the transformation of FKBP52 and βCatenin into S. cerevisiae containing AR and the β-gal reporter was not sufficient for the
reported synergism seen previously within mammalian cell lines. The next step is to now
determine what is missing from the original synergistic complex seen beforehand.
There still remains a variety of other factors that are capable of causing an up-regulation of
AR activity. Glucocorticoid receptor interacting protein 1 (GRIP1), a member of the p160 family
of steroid receptor coactivators, also synergistically enhances AR function (Li et al., 2004).
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Figure 3.1: Yeast Reporter Assay Testing AR Reporter Expression in the Presence of β-Catenin
and/or FKBP52.

Using either a 10, 20 or 30 nM concentration of Dihydrotestosterone (DHT) the resulting βgalactosidase expression levels act as a direct quantitative measurement of steroid hormone
receptor function. Yeast cells were lysed and immunoblotted against β-Catenin, FKBP52, AR,
and L3 (loading control)
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GRIP1 possesses 3 LxxLL motifs that allow for interaction with the AF-2 site in AR’s LBD.
GRIP1 is capable of directly binding to β-Catenin through its AD2 domain and synergism is lost
in truncated proteins missing this site, suggesting a requirement of the GRIP1/β-Catenin
complex. The secondary coactivator known as Coactivator-associated arginine methyltransferase
1 (CARM1), a histone modifying enzyme, is recruited to DNA bound AR through the AD2
domain of GRIP1 (Koh et al., 2002). Interestingly, it was also found to directly interact with βCatenin and aid in its synergism of AR. In addition, the chaperone regulator BAG-1 isoform
known as BAG1-L is capable of significantly increasing AR-induced transactivation of reporter
genes (Froesch et al., 1998). AR mediated transcription was also found to be affected by the Wnt
signaling pathway protein known as ICAT (Zhuo et al., 2011). Expression of ICAT enhanced
AR function for both endogenous and exogenously expressed receptors. This enhancement of
AR activity is believed to be mediated purely through β-Catenin, as it remains one of the few
proteins ICAT is reported to bind to. ICAT is a somewhat newly characterized enhancer of AR
activity and will be further explored.
Within the cell, ICAT’s main role is the disruption of the canonical wnt signaling pathway.
This pathway initiates with the expression of lipid-modified signaling glycoprotein known as
wnts. During the cells “wnt-on” state, wnts form a complex with frizzled receptors and
LRP5/LRP6 coreceptors (Nusse., 2005). Following receptor activation the β-Catenin destruction
complex is inhibited preventing the phosphorylation, ubiquitination, and degradation of free
cytoplasmic β-Catenin (Aberle et al., 1997; Hart et al., 1998; Polakis., 1999). This protein then
begins to accumulate and translocate into the nucleus. Within the nucleus, β-Catenin forms a
complex with LEF1/TCF and acts as a transcriptional co-activator of various genes, such as cmyc, and cyclin D1, both of which play pivotal roles in cell growth, proliferation, and
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Figure 3.2: Structure of ICAT Interacting With β-Catenin.
The N-terminus 3-helix bundle (shown in fuchsia) of ICAT binds to armadillo repeats 11 and 12
of β-Catenin. The extended C-terminus region (shown in red) binds along the positively charged
groove formed along repeats 5-9. Lys312 and Lys435, two important residues involved in the
binding of TCF were found to form salt bridges with the C-terminus tail of ICAT. In vivo studies
demonstrated that the C-terminus region was required for the blocking of TCF to β-Catenin
however, cadherin was still capable of binding despite it having similar binding sites. When
comparing the ICAT bound β-Catenin three-dimensional model with its predicted binding model
in Figure 3 it appears that the ICAT C-terminal tail does not interfere with any protein-protein
interactions required for this binding. Each repeat in β-Catenin consists of three helices colored
in blue (H1), green (H2), and yellow (H3). (Graham et al., 2002).
31

differentiation (He et al., 1998; Shtutman et al., 1999; Tetsu and McCormick, 1999). Colon
cancer can be developed if APC (a member of the β-Catenin destruction complex) or β-Catenin
become mutated or disregulated (Kinzler and Vogelstein 1996; Polakis 1997; Bienz 1999). ICAT
is believed to be a colon cancer tumor suppressor protein due to its ability to prevent β-Catenin
from activating transcription of wnt target genes. ICAT prevents the interaction of β-Catenin and
TCF by binding its N-terminal helical domain to armadillo repeats 11 and 12 and its extended Cterminal tail to repeats 5-10 (Graham et al., 2002). These binding sites, known as charged lysine
buttons, are similar to those that TCF and other β-Catenin ligands interact with, also preventing
the binding of the transcriptional co-activator CBP/p300. While ICAT remains a possible gene
therapy agent for the treatment of colon cancer, compiling evidence suggests there to be an
opposite functional effect seen in prostate cancer cells.
Through the use of immunoprecipitation assays it was demonstrated that endogenous ICAT
forms a complex with β-Catenin and AR (Zhuo et al., 2011). The expression of the N-terminal
domain of ICAT specifically, demonstrated a more pronounced enhancement of β-Catenin/AR
binding apposed to β-Catenin expressed alone. Deregulation of ICAT levels have been reported
within a small percentage of prostate cancer tissues (Reifenberger et al., 2002). Increased levels
were not only found to enhance AR mediated transcription in a dose dependent manner, but also
enhance the growth of prostate cancer cells by roughly thirty percent (Zhuo et al., 2011).
Previous data demonstrated the receptor’s need for β-Catenin however, this was done in a cell
line that expressed the ICAT protein. Due to the gathered information ICAT will be explored as
a possible factor for β-Catenin mediated synergism.
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3.2 Introduction of ICAT Into the FKBP52/Beta-Catenin Yeast Model System
It is understood that β-Catenin and FKBP52 are capable of synergizing androgen receptor
activity within mammalian cells. However, in S. cerevisiae this synergism is seemingly lost. The
small 9kDa protein known as ICAT could have possible implications in a multi-protein complex
located on AR. Following sequence conformation of the newly developed pBEVY-A_ICAT
plasmid this was then transformed into yeast already containing FKBP52 and β-Catenin or their
respective vectors. Unfortunately, expression of the pBEVY-A_ICAT plasmid resulted in
inconsistent reporter-assay data. This is likely due to promoter competition as the majority of the
plasmids transformed into the yeast contain a GPD promoter. However, one notable trend
observed was the increase of β-gal expression within yeast that contained the sequence for
FKBP52 and ICAT.
This increase in reporter expression was somewhat surprising, as previous research has
shown that ICAT interacts with the androgen receptor through β-Catenin (Zhou et al., 2011). In
fact, knock-down of β-Catenin expression resulted in the loss of ICAT mediated AR
potentiation. However, this study took place within LNCap cell lines and the data we see in
figure 3.3 is within, a much simpler model system.
S. cerevisiae contains a much smaller genome and with the help of the Saccharomyces
Genome Database (SGD) we are able to look at specific protein interactions with little
background interruption. It is likely that due to ICAT’s very small size it is unable to properly
bind with AR, and instead requires a shuttling protein (β-Catenin) to promote binding and proper
orientation. Within yeast, β-Catenin could possibly bind AR with too high of an affinity or is
missing other factors necessary for AR activation and instead, acts as a hindrance on FKBP52
synergism. As a great number of proteins are not being expressed in yeast a possible β-Catenin
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Figure 3.3 ICAT is Capable of Potentiating AR in the Presence of FKBP52

FKBP52 expressed in yeast alone is capable of potentiating the androgen receptor. In the
presence of ICAT alone no significant changes occur with reporter expression. However, when
FKBP52 is expressed in conjunction with ICAT we see substantial change in the levels of AR
mediated reporter expression. This indicates that ICAT and FKBP52 may work in concert with
one another to modulate AR transcription.
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release factor could be missing from the AR complex.
3.3 In Vitro Pull-Down Using His-Tagged FKBP52
Due to the significant increase of reporter expression in yeast containing FKBP52 and
ICAT, it is now of interest to determine if these proteins directly interact with one another in
vitro. Myc-FLAG-ICAT was purchased through Origene and purified FKBP2 was utilized.
Using equimolar amounts of FKBP52 and ICAT we do not see any protein being pulled down in
complex with the immunophillin. Instead, FKBP52 is pulled down alone and not with ICAT. It is
possible that FKBP52 and ICAT interact utilizing a third protein or interact on the androgen
receptor surface. Previous studies within our lab determined that β-Catenin was pulled down in
complex with FKBP52 in the absence of AR. It is likely that since β-Catenin is one of the few
proteins known to complex with ICAT, it can possibly mediate FKBP52 and ICAT interactions.
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Figure 3.4 In-vitro Pull Down of 6xHis-Tagged FKBP52

FKBP52 Recombinant protein was incubated with FLAG-tagged ICAT protein in order to assess
protein-protein interactions. It appears that FKBP52 does not pull-down ICAT in an in vitro
model. This suggests that the increase in reporter expression within yeast assays is not likely due
to the two proteins directly interacting with each other. Instead, it is probable these proteins
interact either through the androgen receptor surface or through an uncharacterized multi-protein
complex.
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Chapter 4: Summary, Conclusions And Future Directions
4.1 Summary and Conclusions
β-Catenin and FKBP52 interaction with AR results in a drastic upregulation of AR
mediated transcription within mammalian cell lines (Storer., Unpublished data). This synergism
however, does not appear to occur within the S. cerevisiae model system. Other factors required
for AR activation are likely not present within yeast. The β-Catenin binding protein known as
ICAT, has been demonstrated to modulate AR activity, specifically in the presence of β-Catenin
(Zhuo et al., 2011). No known homolog of ICAT exists within yeast as this remains a possible
source of AR/β-Catenin/FKBP52 synergism. ICAT binds to β-Catenin within armadillo repeats
5-12 and also is found to form a ternary complex with β-Catenin and AR in vivo (Graham et al.,
2002). FKBP52 was previously demonstrated to directly bind to β-Catenin in vitro. It is likely
that the FKBP52/β-Catenin/AR complex also includes the binding of ICAT at a site near the AF2 surface where β-Catenin is understood to interact. A conformational change within the receptor
or the development of an interaction surface that will allow the binding of other effector proteins
could be responsible for the potentiation caused by FKBP52’s proline rich loop interaction with
AR’s BF3 surface.

4.2 Future Directions
Experiments looking at the interaction between FKBP52 and β-Catenin within a yeast
model system resulted in the conclusion that there may be a much larger multi-protein complex
involved in β-Catenin/AR synergism within mammalian cells. In fact, we were able to determine
that the small wnt-signaling pathway protein, ICAT, has possible implications in this complex.
Development of an ICAT knockout prostate cancer cell line would give us data as to how the
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absence of this protein would effect β-Catenin’s and FKBP52’s potentiation on AR. Also, It
would be interesting to determine if the addition of β-Catenin within the in vitro pull-down
would result in the three proteins interacting with one another. β-Catenin is one of the few
proteins known to bind to ICAT, so it would be surprising if these three would be unable to
complex with one another. In addition, the use of tagged recombinant proteins could have an
effect on their binding to one another. Co-immunoprecipitation from a prostate cancer cell line
would be another important experiment in the future to determine if this is effect seen in vivo.
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